Market Cap | 257 | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | 627.24k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -100.00% |
Sales | 25.84k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -100.00% |
Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -100.00% |
Recommedations | - | Quick Ratio | 0.01 | Shares Outstanding | 662.50M | 52W Low Chg | - |
Insider Own | 0.09% | ROA | -8.06% | Shares Float | 644.67M | Beta | -1,268.06 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00000 |
Gross Margin | - | Profit Margin | 2,427.51% | Avg. Volume | 291,487 | Target Price | - |
Oper. Margin | -4,252.19% | Earnings Date | - | Volume | 50,000 | Change | 0.00% |
CannaPharmaRX, Inc. evaluates, negotiates, acquires, and develops various cannabis cultivation projects in Canada. The company is based in Calgary, Canada.